Clinical Trials List
2018-11-30 - 2025-12-31
Phase I
Terminated6
ICD-10C50.011
Malignant neoplasm of nipple and areola, right female breast
ICD-10C50.012
Malignant neoplasm of nipple and areola, left female breast
ICD-10C50.019
Malignant neoplasm of nipple and areola, unspecified female breast
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9174.0
Malignant neoplasm of female breast, nipple and areola
-
Trial Applicant
PAREXEL INTERNATIONAL CO., LTD.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Sheau-Fang Yang Division of Hematology & Oncology
- 甘蓉瑜 Division of Hematology & Oncology
- Chieh-Han Chuang Division of Hematology & Oncology
- Fu Ouyang Division of Hematology & Oncology
- 徐旭亮 Division of Ophthalmology
- 巫承哲 Division of Hematology & Oncology
- Fang-Ming Chen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Yung-Chang Lin Division of General Surgery
- Chan-Keng Yang Division of General Surgery
- Wen-Chi Shen Division of General Surgery
- Mengting Peng Division of General Surgery
- 沈士哲 Division of General Surgery
- Wen-Ling Kuo Division of General Surgery
- 周旭桓 Division of General Surgery
- Chi-Chang Yu Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 郭懿萱 Division of Ophthalmology
- Chun-Yu Liu Division of Hematology & Oncology
- 林燕淑 Division of General Surgery
- Chi-Cheng Huang Division of General Surgery
- 賴亦貞 Division of Radiology
- 陳柏方 無
- 陳彥蓁 Division of General Surgery
- Yi-Fang Tsai Division of General Surgery
- 許志堅 無
- 邱仁輝 Division of General Surgery
- Ta-Chung Chao Division of Hematology & Oncology
- Jiun-I Lai Division of Hematology & Oncology
- 鄭涵方 無
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Kuo-Ting Lee Division of General Surgery
- Jui-Hung Tsai Division of Hematology & Oncology
- Shang-Hung Chen Division of Hematology & Oncology
- Ya-Ting Hsu Division of Hematology & Oncology
- Ya-Ping Chen Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 張端瑩 Division of Hematology & Oncology
- 林季宏 Division of Hematology & Oncology
- Wei-Wu Chen Division of Hematology & Oncology
- 陳怡君 Division of Hematology & Oncology
- 魏以宣 Division of Ophthalmology
- WEI-LI MA Division of Hematology & Oncology
- Ann-Lii Cheng Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- Yao-Chung Wu Division of General Surgery
- Liang-Chih Liu Division of General Surgery
- Chih-Jung Chen Division of General Surgery
- Chen-Teng Wu Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
36 participants
-
Global
305 participants
